0000899243-21-034137.txt : 20210825
0000899243-21-034137.hdr.sgml : 20210825
20210825160025
ACCESSION NUMBER: 0000899243-21-034137
CONFORMED SUBMISSION TYPE: 3/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210617
FILED AS OF DATE: 20210825
DATE AS OF CHANGE: 20210825
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Angermayer Christian
CENTRAL INDEX KEY: 0001845872
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40493
FILM NUMBER: 211206906
MAIL ADDRESS:
STREET 1: BLOCK A, APT.12
STREET 2: IL-PIAZZETTA, TOWER ROAD
CITY: SLIEMA
STATE: O1
ZIP: SLM1605
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ATAI Life Sciences N.V.
CENTRAL INDEX KEY: 0001840904
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: P7
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 180 VARICK STREET
CITY: NEW YORK
STATE: NY
ZIP: 10014
BUSINESS PHONE: (617) 699-5876
MAIL ADDRESS:
STREET 1: 180 VARICK STREET
CITY: NEW YORK
STATE: NY
ZIP: 10014
FORMER COMPANY:
FORMER CONFORMED NAME: ATAI Life Sciences B.V.
DATE OF NAME CHANGE: 20210115
3/A
1
doc3a.xml
FORM 3/A SUBMISSION
X0206
3/A
2021-06-17
2021-06-17
0
0001840904
ATAI Life Sciences N.V.
ATAI
0001845872
Angermayer Christian
66 & 67, BEATRICE, AMERY STREET
SLIEMA
O1
SLM1707
MALTA
1
0
1
0
Common Shares
27805200
I
By Apeiron Investment Group Ltd.
Convertible Notes
Common Shares
2367200
I
By Apeiron Investment Group Ltd.
The reporting person's original Form 3 and subsequently filed Form 4 inadvertently understated this amount by 8,320,000 shares.
Apeiron Investment Group Ltd. is the co-managing member of Presight Capital Management I, LLC, which is the general partner of Presight II, L.P. Therefore, Apeiron Investment Group Ltd. may be deemed to share beneficial ownership of the Common Shares held by Presight II, L.P. Apeiron Investment Group Ltd. is owned and controlled by Christian Angermayer. Mr. Angermayer may be deemed to have beneficial ownership over the shares held by Apeiron Investment Group Ltd. and Presight II, L.P.
The Convertible Notes are currently exercisable and will mature on September 30, 2025.
The reporting person's original Form 3 inadvertently overstated this amount by 5,952,800 shares.
The conversion price for the Convertible Notes is Euro 17.00 per share.
/s/ Ryan Barrett, Attorney-in-fact
2021-08-25